西布曲明和二甲双胍单用及联合应用治疗肥胖症的疗效和安全性

目的:评价西布曲明和二甲双胍单用及联合应用治疗单纯性肥胖的疗效与安全性.方法:将本院肥胖专科门诊137例年龄18～65岁、体重指数25～40 kg/m2的单纯性肥胖患者随机分为三组:二甲双胍治疗组(A组),口服盐酸二甲双胍0.5 g/次,3次/d;西布曲明治疗组(B组),口服盐酸西布曲明5 mg/次,1次/d;二甲双胍和西布曲明联合治疗组(C组),服法同上述两组.结果:有用病例数为8l例,经12 w治疗,与治疗前比,A组体重下降平均为(1.8±1.3)kg(P＜0.05),B组为(4.6±1.6)kg(P＜0.01),C组为(5.6±1.9)kg(P＜0.01).B、C组与A组比差异有显著性(P＜0.01);C组与B组比差异有显著性(P＜0.05).A组在治疗第12周与第8周相比体重下降的差异无显著性(P＞0.05),其余两组随着治疗时间的延长,其体重呈持续性下降,差异有显著性(P＜0.05).同时显著性下降的指标还有体重指数、腰围、臀围、体脂含量和身体脂肪率(P＜0.05或P＜0.01).不良反应发生率分别为A组12.0%,B组26.7%,C组26.9%,B、C组与A组比较差异有显著性(P＜0.05),B、C组两组间比较差异无显著性(P＞0.05).但这些不良反应多为一过性,症状轻微,大多在4～8 w内消失,不影响继续治疗.结论:①三种治疗方案对减肥均有疗效,其中西布曲明和二甲双胍联合治疗疗效最佳,单用西布曲明疗效次之,而单用二甲双胍疗效最差.②西布曲明单用及联合二甲双胍的减肥疗效呈持续性,其中两药联合减肥疗效更佳,提示两药在减肥过程中可能起协同作用;而二甲双胍在治疗初期(4～8w)疗效好,后期疗效不佳.③上述两药联合应用的安全性和耐受性较好,适于对单纯性肥胖患者的治疗.     

西布曲明治疗单性肥胖的临床研究

目的：评价西布曲明治疗单纯性肥胖病的临床疗效和安全性，并比较西布曲明和安慰剂对静息代谢率的影响。方法：采用随机，双盲，安慰剂平行对照，多中心的临床研究方法，对58例单纯性肥胖作为期24周的临床观察。结果：1．西布曲明能明显降低肥胖的各项指标，包括体重，体重指数，腰围，臀围，与治疗前相比，P＜0．0001，而安慰剂组前后相比无显著差异。2．两组治疗前后血常规及生化指标均显著差异（P＜0．05）。3．西布曲明在治疗4，8，12周心率及舒张压有明显升高，但仍在正常范围内，安慰剂组无明显变化。西布曲明及安慰剂组静息代谢率的变化无明显差异。结论：西布曲是有明显的减肥作用，对静息代谢无明显影响，但西布曲明能明显增加心率，升高舒张压。     

盐酸西布曲明治疗单纯性肥胖的疗效与安全性

目的 :评价盐酸西布曲明治疗单纯性肥胖患者的疗效与安全性。方法 :采用随机、双盲、安慰剂平行对照研究方法 ,选择 80例年龄 18～ 6 0岁 ,体重指数≥ 2 5kg/m2 的单纯性肥胖患者 ,随机分为两组 :口服盐酸西布曲明片 (治疗组 ) 10mg/d ;口服安慰剂片 (对照组 )每天 1片共 12周。结果 :有效病例数为 6 6例 ,其中治疗组 31例 ,对照组 35例 ;经 12周治疗 ,治疗组体重平均降低值为 (2 .7± 2 .5 )kg ,显著大于对照组 (- 0 .1± 1.8)kg(P <0 .0 1) ;治疗组不良反应发生率为 5 8.0 %,高于对照组 2 5 .7%(P <0 .0 5 ) ,但症状轻 ,多在 1～ 2周内消失 ,不影响继续治疗。结论 :盐酸西布曲明 10mg/d能有效降低体重 ,治疗的安全性及耐受性较好 ,适用于单纯性肥胖患者的治疗。     

西布曲明治疗单纯性肥胖的临床研究

目的 :评价西布曲明治疗单纯性肥胖病的临床疗效和安全性 ,并比较西布曲明和安慰剂对静息代谢率的影响。方法 :采用随机、双盲、安慰剂平行对照、多中心的临床研究方法 ,对 5 8例单纯性肥胖作为期 2 4周的临床观察。结果 :1.西布曲明能明显降低肥胖的各项指标 ,包括体重、体重指数、腰围、臀围 ,与治疗前相比 ,P <0 .0 0 0 1,而安慰剂组前后相比无显著差异。 2 .两组治疗前后血常规及生化指标均无显著差异 (P >0 .0 5 )。 3 .西布曲明在治疗 4、8、12周心率及舒张压有明显升高 ,但仍在正常范围内 ,安慰剂组无明显变化。西布曲明及安慰剂组静息代谢率的变化无明显差异。结论 :西布曲明有明显的减肥作用 ,对静息代谢率无明显影响 ,但西布曲明能明显增加心率 ,升高舒张压。     

西布曲明治疗超重和单纯性肥胖患者停药1年后体质量的变化

目的:对服用减肥药西布曲明(sibutramine)国产制剂停药1年后超重和单纯性肥胖患者体质量变化进行评价.方法:将75例参加西布曲明Ⅱ期临床药物试验的超重及单纯性肥胖患者分为西布曲明组(43例)和安慰剂组(32例),分别在停止试验后12、24、48周进行体质量、体脂含量、腰围、血胆固醇、三酰甘油、血糖、血压、不良反应等的随访观察.结果:通过48周的随访,停药48周的西布曲明组体质量、体质量指数、体脂含量、腰围比与安慰剂组相比也无明显差异,与治疗前相比也无明显差异(P>0.05),与治疗刚结束时比较有显著差异(P<0.05). 结论:1年的观察表明西布曲明对减肥的体质量无明显维持效果,提示停药反跳.     

单纯性肥胖患者血清IL-6水平的变化及西布曲明减重治疗对其的影响

目的:观察单纯性肥胖患者血清IL-6水平及西布曲明减重治疗对其的影响.方法:45例单纯性肥胖患者分别接受西布曲明(25例)和安慰剂(20例)治疗24周,治疗前后测量患者的体质量、腰围、空腹血糖、胰岛素及IL-6的浓度,计算体质量指数(BMI)和胰岛素抵抗指数(HOMA-IR),并与正常对照组(16例)进行比较.结果:单纯性肥胖患者的体质量、BMI、腰围均明显高于正常对照组(P<0.005),经过24周治疗后,单纯性肥胖患者的体质量、BMI和腰围均有明显下降(P<0.005,P<0.05),但西布曲明治疗组下降的程度明显高于安慰剂组(P<0.005);与正常对照组比,单纯性肥胖患者空腹血清IL-6、胰岛素水平及HOMA-IR明显升高(P<0.005).西布曲明治疗后,血清IL-6、胰岛素水平及HOMA-IR较治疗前明显下降(P<0.005),而安慰剂组血清胰岛素水平及HOMA-IR较治疗前下降(P<0.05),IL-6有下降趋势,但P>0.05.单纯性肥胖患者血清IL-6水平与BMI、腰围、空腹胰岛素及HOMA-IR密切相关(P<0.05,P<0.005,P<0.01).西布曲明组的血清IL-6的下降与BMI、HOMA-IR的下降呈明显正相关(P<0.05), 与腰围下降相关性更大(P<0.01).结论:单纯性肥胖患者血清IL-6水平明显升高,西布曲明治疗后能明显降低血清IL-6水平,可能与体质量减轻,特别是内脏脂肪减少有关.     

穴位埋线联合饮食运动治疗脾虚湿阻型单纯性肥胖的疗效

目的 观察穴位埋线联合饮食运动治疗对脾虚湿阻型单纯性肥胖的疗效。方法 选择2020 年4—10 月于我院传统特色诊疗中心就诊的脾虚湿阻型单纯性肥胖患者60 例,采用随机数字表法分为观察组和对照组,每组各30 例。对照组采用饮食运动治疗,观察组采用穴位埋线联合饮食运动治疗。通过对两组患者的体重、腰围、身体质量指数（BMI）及中医症状评分评价,观察干预12 周前后的改善情况。结果 两组治疗前后体重、BMI 及腰围比较,差异有统计学意义（P＜0.05）;治疗后组间比较,差异无统计学意义（P＞0.05）。两组患者总有效率比较,差异无统计学意义（P＞0.05）。两组治疗前后中医症状评分比较,差异均有统计学意义（P＜0.05）;治疗后两组中医症状评分比较,差异有统计学意义（P＜0.05）。结论 穴位埋线联合饮食运动或单纯饮食运动干预均能显著改善脾虚湿阻型单纯性肥胖患者的体重、BMI、腰围及中医症状评分,其中饮食运动干预因素对疗效影响可能更为显著,增加了穴位埋线的饮食运动对中医症状的改善更为显著。     

达体朗治疗酒依赖患者焦虑抑郁障碍的有效性和安全性研究

目的 探讨达体朗治疗酒依赖患者焦虑抑郁症状的有效性和安全性.方法 采用随机、双盲、安慰剂对照的方法把40例符合纳入和排除标准的患者分成达体朗组和安慰剂组,每组各20人.每个患者均口服安慰剂或达体朗日3次,每次1片,疗程均为8周.在入组前、入组2周和8周后分别进行汉密尔顿焦虑评分量表和抑郁评分量表评分.结果 2周后两组汉密尔顿焦虑评分比较差异无显著性(P＞0.05),汉密尔顿抑郁评分比较差异有显著性(P＜0.05);8周后两组汉密尔顿焦虑和抑郁评分比较差异有显著性(P＜0.05或P＜0.01).达体朗组8周后显示治疗焦虑有效率20%,治疗抑郁有效率90%.结论 达体朗是改善酒依赖患者焦虑抑郁症状的有效而且安全性较高的药物.     

西布曲明治疗肥胖症的临床观察

目的　观察国产西布曲明 (Sibutramine)治疗肥胖症的临床疗效。方法　治疗组 3 1例给予西布曲明 10mg ,每日 1次 ;对照组 2 9例给予安慰剂 10mg ,每日 1次。两组均治疗 2 4周。 结果　发现与安慰剂组相比 ,西布曲明可显著减轻肥胖患者体重 (平均 6 12kg ,P <0 0 1) ,体重指数 (BMI)和腰围 (W ) (P <0 0 5 )。且各种生化指标无明显改变。除口干、头昏外 ,未见严重的不良反应。结论　西布曲明能有效降低肥胖患者体重、体重指数、腰围。     

催产素治疗单纯性肥胖的疗效与安全性研究

目的 探讨催产素（OXT）鼻内给药治疗单纯性肥胖患者的疗效与安全性。方法 采用随机、双盲、 安慰剂对照的方法将符合研究要求的30 例单纯性肥胖患者分为治疗组和安慰剂组,分别接受催产素鼻喷剂和安 慰剂（生理盐水）鼻喷剂,治疗12 周。观察两组治疗前后的体重、体重指数（BMI）、腰围、臀围、血脂及肝 肾功能变化情况,评价其临床疗效和安全性。用酶联免疫法（ELISA）检测两组治疗前0 周和治疗后12 周血 清C 反应蛋白（CRP）和脂联素（APN）水平。结果 治疗后12 周,治疗组体重、BMI、腰围、臀围下降幅度与 安慰剂组比较,差异有统计学意义（P <0.05）,治疗组大于安慰剂组。治疗组治疗后12 周TC、TG、LDL-C 与 治疗前比较,差异有统计学意义（P <0.05）,均有所下降,而HDL-C 在治疗前后差异无统计学意义（P >0.05）。 治疗后12 周,治疗组TC、TG、LDL-C 与安慰剂组比较,差异有统计学意义（P <0.05）,治疗组低于安慰剂 组。治疗后12 周,治疗组ALT 与治疗前比较,差异有统计学意义（P <0.05）,治疗后12 周较治疗前下降。治疗 组AST、Scr、BUN 治疗前后差异无统计学意义（P >0.05）。与治疗前比较,治疗后12 周治疗组CRP 下降, APN 升高（P <0.05）。与安慰剂组比较,治疗后12 周治疗组CRP 下降,APN 升高（P <0.05）。结论 催产素 可以减轻单纯性肥胖患者体重,还能改善血脂紊乱,改善肥胖慢性炎症状态,未发现有肝肾功能的损害。     

肥胖患者血清瘦素和胰岛素抵抗的关系及西布曲明对其的影响

OBJECTIVE: To assess the relationship between serum leptin and insulin resistance (IR) in obesity, and to investigate the effects of sibutramine on obesity, serum leptin and IR. METHODS: Seventy obese subjects [body mass index (BMI) > or =25 kg/m2] were randomly divided into 2 groups: group B (sibutramine 10 mg/day) and group C (a placebo tablet/day). Both had been treated for 12 weeks. Another 30 healthy adults served as the normal control (group A: BMI < 23 kg/m2). Their height, body weight, waist and hip circumference, fasting plasms glucose (FPG), fasting plasma insulin (FINS), and serum leptin were examined at the baseline and 12 weeks after the therapy. Insulin senstivity index (ISI) was calculated [ISI = 1/(FPG x FINS)]. Multiple linear regression analysis and partial correlation were performed on serum leptin. RESULTS: The body weight, BMI, waist and hip circumference decreased significantly after the 12 week-treatment with sibutramine in group B (P < 0.01), but those indexes did not change after the treatment with placebo in group C (P > 0.05). The levels of leptin and FINS were higher (P < 0.01), but ISI was lower (P < 0.01) both in group B and C compared with those in group A at the baseline. The levels of serum leptin and FINS decreased (P < 0.01), and ISI increased significantly (P < 0.05) after the treatment with sibutramine in group B, while those indexes did not change after the treatment with placebo in group C. The most important factors to influence serum leptin level were listed as follows: sex > BMI > FINS > ISI (R2 = 0.661, F = 12.662, P < 0.01). The lep- tin was positively correlated with FINS (r = 0.597, P < 0.01) , but negatively correlated with ISI (r = -0.468, P < 0.01 ) after eliminating the effects of sex and BMI. Conclusion Leptin resistance and insulin resistance exist in obesity, and serum leptin is associated with IR. Treatment with sibutramine significantly reduces the body weight and leptin, increases insulin senstivity, and improves IR.     

A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects

Objectives To assess weight loss efficacy ,safety and tolerability of sibutramine in simple obese subjects.Methods Randomized, double-blind, placebo-controlled clinical trial. Four hospital outpatient clinics in Shanghai, Chongqing, Shandong and Tianjin, respectively. Participants: 233 men and women, 18-65 years old, with body mass index (BMI) ranging from 27 to 40*!kg/m2 were randomly divided into an intervened group and a placebo control group. Sibutramine 10 mg or placebo once a day. Main outcome measures: Body weight, routine laboratory and clinical safety monitoring.Results Of 233 eligible patients, 120 received sibutramine and 113 received placebo. Weight reduction was significantly greater in the intervened group (6.8±3.1) kg than the placebo control group (0.48±2.6) kg from week 4 onwards to week 24 (P<0.001). Some minor side effects were noticed in the subjects who took sibutramine. But the symptoms were light and short term. Sibutramine was will tolerated.Conclusions Sibutramine 10*!mg once a day is an effective an safe therapy for weight reduction in simple over-weighted and obese subjects.     

Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial

CONTEXT: Adolescent obesity is becoming a national public health problem. Weight-loss medications including sibutramine facilitate weight control in adults and could be used with obese adolescents in combination with behavior therapy (BT). OBJECTIVE: To examine whether increased weight loss in obese adolescents is induced when sibutramine is added to a family-based, behavioral weight control program. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial consisting of 82 adolescents aged 13 to 17 years with a body mass index (BMI) of 32 to 44 conducted from March 1999 to August 2002 at a university-based clinic for 6 months, followed by open-label treatment during months 7 to 12. INTERVENTIONS: For the first 6 months, participants received either BT and sibutramine or BT and placebo. From months 7 to 12, all participants received sibutramine in open-label treatment. MAIN OUTCOME MEASURES: Percentage change in BMI; systolic and diastolic blood pressure and pulse; and hunger. RESULTS: In intention-to-treat analysis at month 6, participants in the BT and sibutramine group lost a mean (SD) of 7.8 kg (6.3 kg) and had an 8.5% (6.8%) reduction in BMI, which was significantly more than weight loss of 3.2 kg (6.1 kg) and reduction in BMI of 4.0% (5.4%) in the BT and placebo group. Significantly greater reductions in hunger (P =.002) also were reported by participants who received BT and sibutramine. From months 7 to 12, adolescents initially treated with sibutramine gained 0.8 kg (10.5 kg) with continued use of the medication, whereas those who switched from placebo to sibutramine lost an additional 1.3 kg (5.4 kg). Medication dose was reduced (n = 23) or discontinued (n = 10) to manage increases in blood pressure, pulse rate, or other symptoms. CONCLUSIONS: The addition of sibutramine to a comprehensive behavioral program induced significantly more weight loss than did BT and placebo. Until more extensive safety and efficacy data are available, medications for weight loss should be used only on an experimental basis in adolescents and children.     

Long-term weight loss with sibutramine: a randomized controlled trial

CONTEXT: Treatment of obesity requires long-term therapy, which can be hampered by difficulties in achieving patient compliance. The effectiveness of sibutramine hydrochloride in treating obesity has been shown in randomized controlled trials. OBJECTIVE: To compare the effectiveness of 2 distinct sibutramine regimens with each other and with placebo for weight reduction among obese persons. DESIGN: Randomized, double-blind, parallel-group placebo-controlled trial from April 1997 to September 1998. SETTING: One hundred eight private practices and 3 outpatient departments of university hospitals in Germany. PATIENTS: A total of 1102 obese adults (body mass index, 30-40 kg/m(2)) entered the 4-week open-label run-in period with 15 mg/d of sibutramine, 1001 of whom had weight loss of at least 2% or 2 kg were randomized into the 44-week randomized treatment period. INTERVENTIONS: Patients were randomly assigned to receive 15 mg/d of sibutramine continuously throughout weeks 1-48 (n = 405); 15 mg/d of sibutramine intermittently during weeks 1-12, 19-30, and 37-48, with placebo during all other weeks (n = 395); or placebo for weeks 5-48 (n = 201). MAIN OUTCOME MEASURE: Weight loss during the randomized treatment period, compared among all 3 groups. RESULTS: Mean weight loss in the intention-to-treat population during the 44-week randomized treatment period was 3.8 kg (4.0%) in patients receiving continuous therapy (95% confidence interval [CI], - 4.42 to - 3.20 kg) and was 3.3 kg (3.5%) in patients receiving intermittent therapy (95% CI, - 3.96 to - 2.66 kg), vs a mean weight gain of 0.2 kg (0.2%) (95% CI, - 0.60 to 0.94 kg) in patients receiving placebo. Therapeutic equivalence of the 2 active treatments could be shown. Although there was a greater weight loss in the continuous than in the intermittent group, this difference was nonsignificant (P =.28) and the 95% CIs were within the predefined range of therapeutic equivalence-0 +/-1.5 kg (-1.37 to 0.28 for the intent-to-treat population). Overall weight loss during the 48-week period was 7.9 kg and 7.8 kg in the continuous and intermittent groups, respectively, but was 3.8 kg in the sibutramine run-in placebo group. Waist circumference reduction, triglyceride levels, and high-density lipoprotein cholesterol concentrations were also positively influenced by sibutramine treatment. Systolic and diastolic blood pressures were stable across all 3 groups. Overall, adverse events occurred at similar frequencies across all treatment groups, but the proportion was lowest in the group receiving intermittent therapy. CONCLUSIONS: Sibutramine, administered for 48 weeks to a typically obese population, results in clinically relevant weight loss compared with placebo. Regarding effectiveness, continuous and intermittent sibutramine therapies are equivalent and the safety profiles for both treatments are comparable.     

肥胖患者血清瘦素和胰岛素抵抗的关系及西布曲明对其的影响

目的 :观察肥胖患者血清瘦素和胰岛素抵抗的关系及西布曲明治疗单纯性肥胖的疗效及对瘦素和胰岛素抵抗的影响。方法 :单纯性肥胖患者 [体重指数 (BMI)≥ 2 5kg/m2 ]70例 ,随机分为B组 (口服盐酸西布曲明片10mg/d)和C组 (口服安慰剂 1片 /d) ,共治疗 12周 ;另选 30例年龄匹配的健康正常人作为对照组 (A组 ) :BMI<2 3kg/m2 ,均检测身高、体重、腰围、臀围 ,观察空腹血糖 (FPG)、血清空腹胰岛素 (FINS)、血清瘦素 (leptin)的变化 ,计算胰岛素敏感指数 [ISI=1/ (FPG×FINS) ],对瘦素与上述指标和ISI的相关性用多元逐步回归分析和偏相关分析。结果 :治疗 12周后 ,B组体重、BMI ,腰围、臀围显著下降 (P <0 .0 0 1) ,但C组上述指标无明显变化。两组肥胖受试者在治疗前血清瘦素、胰岛素水平明显高于A组 (P <0 .0 1) ,ISI明显低于A组 (P <0 .0 1) ;但B组用西部曲明治疗后血清瘦素、胰岛素水平明显下降 (P <0 .0 1) ,ISI水平显著升高 (P <0 .0 5 ) ;而C组用安慰剂治疗后上述指标无变化。在肥胖受试者中 ,影响瘦素最主要的因素依次为性别、BMI,胰岛素、ISI(R2 =0 .6 6 1,F =12 .6 6 2 ,P <0 .0 1) ,去除性别、BMI的影响后 ,瘦素与胰岛素呈著显正相关 (r=0 .5 97,P <0 .0 1) ,与ISI明显负相关 (r= 0 .4 6 8,P <0 .0     

西布曲明对肥胖患者血清瘦素及胰岛素水平的影响

目的 :探讨西布曲明 (Sibutramine)对肥胖患者血清瘦素及胰岛素水平的影响。　方法 :测定 35例单纯性肥胖患者服用西布曲明前后体重指数 (BMI)、腰臀比 (WHR)及血清瘦素、胰岛素水平的变化。　结果 :肥胖组用药前BMI、WHR、空腹瘦素和胰岛素水平均明显高于正常组 ,服用西布曲明后 ,上述指标均明显下降。且瘦素水平的变化在排除性别影响后更为显著。　结论 :西布曲明作为一种口服减肥药 ,不仅能减轻肥胖患者的体重 ,而且能明显降低肥胖患者的空腹瘦素和胰岛素水平     

肥胖者血清高密度脂蛋白亚类组成的研究

OBJECTIVE: To investigate the change of the contents of serum HDL subclasses in obese subjects. METHODS: Contents of serum HDL subclasses in healthy controls(n = 64) and obese subjects(n = 58) were determined by two-dimensional gel electrophoresis associated with immunodetection method. RESULTS: The pre-beta 1 HDL, HDL3c and HDL3b contents increased significantly (P < 0.001) and the HDL2b content decreased significantly (P < 0.001) in obese subjects as compared with those in healthy controls. In male obese subjects, the pre-beta 1 HDL and HDL3c levels were significantly higher(P < 0.01 and P < 0.05, respectively) and HDL2b level was significantly lower(P < 0.05), compared with those in female obese subjects. In male control subjects, the level of pre-beta 1 HDL was significantly higher than that in female subjects. In obese subjects, the concentrations of BMI and serum TG had positive correlation with those of pre-beta 1 HDL(r = 0.382, P < 0.001), HDL3c(r = 0.232, P < 0.05) and HDL3b(r = 0.294, P < 0.01) and negative correlation with that of HDL2b(r = -0.304, P < 0.01). CONCLUSION: The particle size of HDL in obese subjects showed a general shift toward smaller size, which indicated that the maturation of HDL could be abnormal in obese subjects. The particle size of HDL was found to be smaller in both obese and control male subjects than in female subjects, suggesting that sex seems to be related to the contents of serum HDL subclasses.     

经阴道完全腹腔镜直肠癌根治术对女性性功能障碍的影响

目的:探讨经阴道腹腔镜直肠癌根治术对女性性功能的影响。方法:选取64例女性直肠癌患者,观察组31例经阴道完全腹腔镜直肠癌根治术,对照组33例常规腹腔镜直肠癌根治术,分别于术后6、12个月进行问卷调查或电话随访,记录患者术后的性功能变化情况,比较2种手术方式对女性患者性功能的影响。结果:术后6个月观察组患者阴道湿润度、性交痛和性生活满意度均差于对照组(P<0.05~P<0.01)。术后12个月,2组各项性功能指标差异均无统计学意义(P>0.05)。结论:阴道完全腹腔镜直肠癌根治术后由于阴道干燥,短期内会对女性性功能造成一定影响,但随时间推移可恢复到与行常规腹腔镜手术相同的水平。